Navigation Links
Study demonstrates link between reclassification of cannabis and cannabis psychosis
Date:7/18/2013

Researchers from the University of York have demonstrated that the change in cannabis declassification in 2009 has coincided with a significant increase in hospital admissions for cannabis psychosis - rather than the decrease it was intended to produce.

The UK Misuse of Drugs Act (1971) divided controlled drugs into three groups A, B and C with descending criminal sanctions attached to each class. Cannabis was originally assigned to Group B, but in 2004, it was transferred to the lowest risk group, Group C.

In 2009, on the basis of increasing concerns about a link between high strength cannabis and schizophrenia, it was moved back to Group B.

Researchers from the University's Department of Health Sciences examined admissions to psychiatric hospitals in England between 1999 and 2010 to explore whether the reclassifications in 2004 and 2009 were associated with changes in the admissions rate for cannabis psychosis.

They found that there was a significantly increasing trend in admissions from 1999 to 2004, but following the reclassification of cannabis from B to C in 2004, there was a decline until 2009. Following the second reclassification back to class B in 2009, there was once again a significant increase in admissions.

The study was led by Ian Hamilton from York's Department of Health Sciences, an expert on the relationship between substance misuse and mental health. The results are published in the International Journal of Drug Policy.

Psychosis describes a range of symptoms, such as distortions of reality, hearing voices, difficulty in thinking and problems with motivation.

Ian Hamilton said: "Our research shows an interesting relationship between the Government's decision to reclassify cannabis and the rate of hospital admissions for cannabis psychosis. It is significant as the Government's argument for reclassification was made on the basis that the stronger forms of cannabis known as 'skunk' are more likely to lead to mental health problems such as psychosis. However, our research challenges this.

"While our study shows a statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis, it is in the opposite direction to that predicated by the presumed relationship between the two."

The authors say the reasons for the statistical association between the reclassification of cannabis and hospital admissions for cannabis psychosis are unclear.

Ian Hamilton said: "The association is unlikely to be due to changes in cannabis use over this period, but possible explanations include changes in policing and systematic changes in mental health services unrelated to classification decisions."


'/>"/>

Contact: Caron Lett
caron.lett@york.ac.uk
44-019-043-22029
University of York
Source:Eurekalert

Related medicine news :

1. Spectrum Health study first to identify heart attack-causing plaque in living patients
2. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
3. Study of Vanuatu Further Identifies Behaviors That Cause Obesity
4. Study reveals new dietary risk factors for colorectal cancer
5. Undiagnosed pre-diabetes highly prevalent in early Alzheimers disease study
6. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes New Study Linking Pradaxa to Increased Heart Attack Risk
7. Advanced Medical Certification Offers Audiobooks and PDF Study Guides at No Cost Upon Course Purchase
8. Biomarker Market is Estimated to Grow at a CAGR of 14.40% During the Study Period of 2011-2016 – New Report by MarketsandMarkets
9. Besttoolbars Study Reveals New Trend in Online Cashback Marketing
10. Study finds strong pregnancy outcomes for survivors of childhood cancer
11. Study finds potential markers for severity of childhood arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users ... X . Users have total control over position, rotation, distortion, edge softness, edge blur, ... Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... IL (PRWEB) , ... February 24, 2017 , ... The ... the 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. ... Choice will be showcased and the winner revealed at the 31st annual iaedp Symposium, ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... and PETACH TIKVAH, Israel , ... (NASDAQ: BCLI), a leading developer of adult stem cell ... June S. Almenoff , M.D., Ph.D., FACP, and ... Board of Directors.  "Dr. Almenoff and ... appointments come at an exciting time for our company," ...
(Date:2/24/2017)... Following receiving CE Marking in ... AMAR is a major milestone for the country where the device was ... market in Israel   ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and ... Hemophilia market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology: